NADER EL-MALLAWANY to Treatment Outcome
This is a "connection" page, showing publications NADER EL-MALLAWANY has written about Treatment Outcome.
Connection Strength
0.090
-
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
Score: 0.013
-
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
Score: 0.013
-
Clinical characteristics and successful treatment outcomes of children and adolescents with Kaposi sarcoma in Southwestern Tanzania. Pediatr Hematol Oncol. 2022 Feb; 39(1):28-47.
Score: 0.011
-
Recommendations for treating life-threatening Kaposi sarcoma during pregnancy in HIV-positive women in low income countries. Int J STD AIDS. 2020 07; 31(8):724-734.
Score: 0.010
-
Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. Blood Adv. 2019 02 26; 3(4):612-620.
Score: 0.009
-
Hodgkin lymphoma, HIV, and Epstein-Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.008
-
Adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016 05; 173(4):637-50.
Score: 0.008
-
Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. Br J Haematol. 2016 06; 173(5):705-12.
Score: 0.007
-
Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa. Nat Rev Clin Oncol. 2013 10; 10(10):599-604.
Score: 0.006
-
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
Score: 0.005